3M-052-AF

3M-052-AF is a synthetic small molecule agonist of Toll-like receptor 7 and Toll-like receptor 8 (TLR7/8), developed as a vaccine adjuvant to enhance immune responses. It is an imidazoquinoline derivative structurally related to R848 but modified with an 18-carbon fatty acyl chain to improve incorporation into emulsion or liposome-based formulations and minimize systemic distribution. When formulated with alum (aluminum hydroxide) or nanoparticles, it has demonstrated the ability to induce robust, durable antibody responses and strong activation of innate immunity in both nonhuman primate models and humans. In clinical trials, specifically HVTN137A, the combination of BG505 SOSIP.664 HIV trimer antigen with 3M-052-AF/alum was found safe in healthy adults and elicited strong neutralizing antibody titers as well as potent B-cell and CD4+ T-cell responses[2][5][6]. The mechanism of action involves TLR7/8 agonism leading to activation of monocytes, plasmablasts, germinal center B cells, T follicular helper cells, and long-lived plasma cells[1][4]. The drug is being developed primarily for use as a vaccine adjuvant in HIV vaccines but may have broader applications.

Other names

3M-05-AF3M-0523M-052 AF